Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales
03:59pm, Tuesday, 01'st Feb 2022 Zacks Investment Research
CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
06:10pm, Monday, 31'st Jan 2022 Zacks Investment Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
05:43pm, Monday, 31'st Jan 2022 Zacks Investment Research
Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study
05:48pm, Friday, 28'th Jan 2022 Zacks Investment Research
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
05:44pm, Friday, 28'th Jan 2022 Zacks Investment Research
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
03:52pm, Friday, 28'th Jan 2022 Zacks Investment Research
Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
04:36pm, Thursday, 27'th Jan 2022 Zacks Investment Research
In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat
03:26pm, Thursday, 27'th Jan 2022 Zacks Investment Research
Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
11:58am, Wednesday, 26'th Jan 2022 Zacks Investment Research
On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
05:45pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
02:48pm, Monday, 24'th Jan 2022 Zacks Investment Research
Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
05:50pm, Friday, 21'st Jan 2022 Zacks Investment Research
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
03:41pm, Thursday, 20'th Jan 2022 Zacks Investment Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
09:01pm, Monday, 03'rd Jan 2022 GlobeNewswire Inc.
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 03'rd Jan 2022
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of
